Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,366 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease.
Hibi T, Sakuraba A, Watanabe M, Motoya S, Ito H, Sato N, Yoshinari T, Motegi K, Kinouchi Y, Takazoe M, Suzuki Y, Matsumoto T, Kawakami K, Matsumoto T, Hirata I, Tanaka S, Ashida T, Matsui T. Hibi T, et al. Among authors: sato n. J Gastroenterol. 2014 Feb;49(2):254-62. doi: 10.1007/s00535-013-0807-0. Epub 2013 Apr 20. J Gastroenterol. 2014. PMID: 23604570 Clinical Trial.
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
Kobayashi T, Suzuki Y, Motoya S, Hirai F, Ogata H, Ito H, Sato N, Ozaki K, Watanabe M, Hibi T. Kobayashi T, et al. Among authors: sato n. J Gastroenterol. 2016 Mar;51(3):241-51. doi: 10.1007/s00535-015-1102-z. Epub 2015 Jul 11. J Gastroenterol. 2016. PMID: 26162647 Free PMC article. Clinical Trial.
Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.
Suzuki Y, Matsui T, Ito H, Ashida T, Nakamura S, Motoya S, Matsumoto T, Sato N, Ozaki K, Watanabe M, Hibi T. Suzuki Y, et al. Among authors: sato n. Inflamm Bowel Dis. 2015 Sep;21(9):2114-22. doi: 10.1097/MIB.0000000000000475. Inflamm Bowel Dis. 2015. PMID: 26218144 Clinical Trial.
Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study.
Hibi T, Hirohata S, Kikuchi H, Tateishi U, Sato N, Ozaki K, Kondo K, Ishigatsubo Y. Hibi T, et al. Among authors: sato n. Medicine (Baltimore). 2016 Jun;95(24):e3863. doi: 10.1097/MD.0000000000003863. Medicine (Baltimore). 2016. PMID: 27310969 Free PMC article. Clinical Trial.
Physician-patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis.
Matsuoka K, Ishikawa H, Nakayama T, Honzawa Y, Maemoto A, Hirai F, Ueno F, Sato N, Susuta Y, Hibi T. Matsuoka K, et al. Among authors: sato n. J Gastroenterol. 2021 Sep;56(9):843-855. doi: 10.1007/s00535-021-01811-1. Epub 2021 Jul 27. J Gastroenterol. 2021. PMID: 34313863 Free PMC article.
5,366 results